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Original Article
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Background: Renal cell carcinoma (RCC) is traditionally considered to be radioresistant. Radiotherapy 
response rates are believed to improve with hypofractionated, high dose stereotactic body radiotherapy (SBRT). 
However, limited data exist regarding the role of SBRT in the treatment of pulmonary metastases. 
Methods: The working group “Stereotactic Radiotherapy” of the German Society of Radiation Oncology 
analyzed its multi-institutional database of more than 700 patients who received SBRT for pulmonary 
metastases. Treatment was performed at 10 centers between 2001 and 2016. Patients with metastatic RCC 
were included in the study. Tumor characteristics, treatment details, and follow-up data including survival, 
local control (LC), distant metastases, and toxicity were evaluated. 
Results: A total of 46 RCC patients treated with SBRT for 67 lung metastases were identified, who 
received a median total biologically effective dose (BEDiso) at planning target volume (PTV) isocenter of 
117.0 Gy (range, 48.0–189.0 Gy). A median fractional dose of 20.8 Gy at isocenter (range, 6.0–37.9 Gy) 
was administered in a median number of 3 fractions (1–8 fractions). After a median follow-up time of  
28.3 months for all patients, 1- and 3-year LC rates were 98.1% and 91.9%, with corresponding 1- and 3-year 
overall survival (OS) of 84.3% and 43.8%, respectively. Pulmonary metastases treated with BEDiso ≥130 Gy 
showed a trend for superior LC (P=0.054). OS was significantly improved in both uni- and multivariate 
analysis for patients with higher Karnofsky performance scale, lower maximum pulmonary metastasis 
diameter and lack of post-SBRT systemic therapy due to progression (P=0.014; P=0.049; P=0.006). Only 
mild acute and late toxicity was reported.
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Introduction
Renal cell carcinoma (RCC) represents 2–3% of adult 
cancers in the European Union and accounts for 
approximately 34,700 deaths per year (1,2). Although 5-year 
survival for all patients is approximately 74%, survival rates 
are highly dependent on disease stage, declining to 67% 
when locoregional disease (stage III) is detected and 12% 
in patients with distant metastases (3,4). Most patients are 
diagnosed at an early stage, yet nearly one third of these 
patients will suffer from local or distant relapse in the 
course of their disease, and a similar proportion of patients 
present with metastatic spread at first diagnosis (5,6). 
Lung metastases are the most common presentation of 
distant disease, comprising 11–75% of cases, while hepatic 
metastases occur in 20–40% of patients (7-12). 
When distant metastases are diagnosed, systemic 
treatment with targeted agents is usually administered (3). 
However, an oligo-metastatic state has been hypothesized, 
where systemic therapy and potential toxicity might be 
postponed by applying local treatment strategies to all 
evident tumor lesions (13). Furthermore, an objective 
response has been reported in 20–40% of patients, but 
complete response was only detected in 1–3% of cases with 
current targeted drugs (13-16). Consequently, in cases of 
oligoprogression, local ablative treatment to all synchronous 
and metachronous metastases, when technically feasible and 
clinically appropriate, might represent a potentially curative 
approach (13). 
Surgical series for pulmonary metastasectomy as a local 
treatment method of RCC patients report excellent local 
control (LC) in case of complete resection and promising 
3- and 5-year survival rates of 49–66% and 31–58%, 
respectively (17-27). However, some RCC patients are 
medically inoperable due to reduced performance status or 
comorbidities and some pulmonary metastases are technically 
not accessible or resectable. For these patients, stereotactic 
body radiotherapy (SBRT) which utilizes highly conformal 
ablative local doses to the tumor while sparing surrounding 
organs,  has shown encouraging results (5,28-30). 
However, available reports concerning SBRT for RCC 
metastases have pooled heterogeneous data from various 
tumor locations (lung, bone, lymph node, brain, liver, etc.) 
with different sensitivities to high-dose radiation (5,6,28-33). 
This multi-institutional study reports the feasibility, safety, 
and efficacy of SBRT for pulmonary RCC metastases.
Methods
The working group “Stereotactic Radiotherapy” of 
the German Society of Radiation Oncology (DEGRO) 
analyzed its retrospective multi-institutional database 
including more than 700 patients treated with SBRT for 
more than 900 pulmonary metastases. Detailed description 
of the database has been previously published (34-36). For 
the current study, an update of the database was performed 
in April 2017. Patient data from institutions that did not 
participate in this database update were excluded from this 
study. In total, 46 patients with histologically confirmed 
RCC treated with SBRT for 67 pulmonary metastases at 
10 different German centers between 2001 and 2016 were 
analyzed. Each center compiled patient characteristics, 
treatment details, and outcome data in an anonymized 
electronic file and delivered it to the coordinating center, 
where a pooled database was created. The analysis was 
approved by the Ethics committee of the University 
Hospital Heidelberg (S-280/2014).
Pulmonary SBRT was utilized if patients were classified 
medically inoperable, diagnosed with unresectable lung 
metastases or refused surgical resection. Fluoro-deoxy-
glucose positron emission tomography (FDG-PET) 
imaging was only performed in five patients and biopsy 
confirmation was performed when the origin of the 
pulmonary lesion was in question (n=7). All centers used 
risk-adapted fractionation schemes adjusting the number 
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of fractions and single-fraction doses to tumor size and 
location (peripheral vs. central). Metastases were classified 
to be “peripheral” or “central” according to the Radiation 
Therapy Oncology Group (RTOG) definition (37,38). 
Treatment-related toxicity was categorized according to 
CTCAE v4.0.
For correlating radiation doses with clinical results, the 
biological effective dose (BED) was determined assuming: 
an α/β ratio of 10 Gy for the pulmonary metastases. BED 
was calculated using the linear-quadratic model (39):
fractional dose
BED (Gy) = fractional dose  number of fractions 1+
α/β
æ ö´ ç ÷
è ø
LC, overall survival (OS) and distant control (DC) were 
estimated using the Kaplan-Meier method. While LC was 
calculated for each individual pulmonary metastasis, OS and 
DC were determined following SBRT for the first, index 
pulmonary lesion if several pulmonary metastases were 
treated. LC was defined as no progressive disease within 
the high-dose area. Recurrences distant to the treated 
pulmonary metastasis in the same lobe were not classified as 
local but as distant failure. 
Survival curves were compared between groups in 
univariate analysis applying the log-rank test or cox 
regression analysis. Receiver operating characteristics 
(ROC) curves and the Youden’s index were applied to 
determine the optimal cut-off for BED at planning target 
volume (PTV) isocenter (BEDISO). Multivariate cox 
models were performed including all variables which were 
statistically significant in univariate analysis. Multivariate 
analysis was not performed for LC, as no significant 
prognostic factor was identified in univariate analysis. LC, 
OS and DC were analyzed from the start of SBRT until the 
event of interest or the last follow-up visit. A P≤0.05 was 
considered statistically significant. All statistical analyses 
were performed with SPSS software (version 20.0). 
Results
Patient and treatment characteristics
This multi-institutional analysis included data from 
10 centers with extensive lung SBRT experience, of which 
seven were university hospitals. In total, data were collected 
from 46 patients treated with SBRT for 67 pulmonary 
metastases. Most patients were treated for one lung 
metastasis (median: 1 metastasis, range, 1–7 metastases). 
All patients were diagnosed with biopsy-proven metastatic 
RCC and had in median one additional metastasis (range, 
0–15) besides the treated pulmonary lesion(s). Additional 
metastases were located in 77.1% in the lung. Of these 
48.6% were treated with resection and 31.4% underwent 
additional SBRT. Overall, 83% of patients received 
definitive treatment with curative intent (SBRT, definitive 
radiotherapy or surgery, sometimes in combination with 
systemic therapy) to all known sites of metastasis, while 
the remaining 17% were treated with systemic therapy 
including chemotherapy, immunotherapy, or targeted 
agents. In total, 22 patients received systemic therapy prior 
to SBRT. Of these, chemotherapy was administered in 
two patients, followed by immunotherapy in five patients 
and tyrosine kinase inhibitors in 15 patients. SBRT to 
pulmonary metastases was applied at a median 73.8 months 
(range, 3.2 months–28.8 years) following diagnosis of the 
primary tumor. The time interval between diagnosis of the 
pulmonary metastasis and SBRT treatment was found to be 
2.7 months (0.2–83.1 months) in median. Detailed patient 
and treatment characteristics are illustrated in Tables 1 and 2.
OS, LC and systemic progression
Median follow-up time for all patients was 28.3 months 
(range, 0.8–133.8 months) with 1- and 3-year LC rates of 
98.1% and 91.9%, respectively (Figure 1A). Only 3 local 
relapses (4.5%) were detected during the follow-up period 
with a median time to local failure of 26.2 months (range, 
10.5–27.7 months). Univariate analysis revealed a trend 
for increased LC when the BEDISO ≥130 Gy (P=0.054) 
(Figure 1B) (Table 3). Pulmonary metastases treated with a 
BEDISO <130 Gy resulted in a 3-year LC of 83.9%, while receipt 
of a BEDISO ≥130 Gy was associated with a 3-year LC of 100%.
One- and 3-year distant metastases free survival was 
found to be 45.7%, and 17.0%. Distant disease progression 
was the most common pattern of failure, with 69.6% of 
patients (n=32) developing new, out-of-field metastases. 
Distant metastases were mostly detected in the lung (n=26), 
the bone (n=4), the liver (n=4), the brain (n=4), and other 
locations (n=4).
One- and 3-year OS was 84.3% and 43.8% respectively 
(Figure 2). Karnofsky performance score, maximum 
pulmonary metastasis diameter and the lack of admission of 
systemic therapy after SBRT due to disease progression were 
identified as prognostic factors for OS in univariate analysis 
(P=0.010; P=0.011, P=0.001) (Table 3). Furthermore, the 
presence of metachronous metastases was associated with 
a trend towards improved OS compared to synchronous 
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Table 1 Baseline patient and lesion characteristics for 46 patients treated with SBRT for 67 pulmonary metastases
Factors No. of patients/lesions % Median Minimum Maximum
Persons
Age (yr) 46 68.5 35.4 85.1
Sex 46
Male 34 73.9
Female 12 26.1
Pretreatment performance scale (Karnofsky index) (%) 46 90 60 100
Cancer stage at first diagnosis 46
Stage I 10 21.8
Stage II 7 15.2
Stage III 15 32.6
Stage IV (M+) 14 30.4
Histology 46
Clear cell 33 71.7
Other 8 17.4
Unavailable 5 10.9
Grade 46
Grade 1 7 15.2
Grade 2 24 52.2
Grade 3 5 10.9
Unavailable 10 21.7
Pulmonary lesions
Metastasis diameter (cm) 67 2.1 0.6 7.6
Metastasis location 67
Central 13 19.4
Peripheral 54 80.6
Number of metastases 67
Single 12 17.9
Multiple 55 82.1
Time to metastasis 67
Synchronous 3
Metachronous 64
Time interval between SBRT and first tumor diagnosis (years) 67 6.15 0.27 28.8
Systemic therapy before SBRT 67
Yes 35 52.2
No 32 47.8
Table 1 (continured)
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Table 2 SBRT treatment patterns for 67 lung metastases
Dose prescription parameters No. of Lesions % Median Minimum Maximum
Fractional dose at PTV isocenter (Gy) 67 20.8 6.0 37.9
Number of fractions 67 3 1 8
BEDPTV (PTV periphery) (Gy) 67 84.4 35.7 180.0
BEDISO (PTV isocenter) (Gy) 67 117.0 48.0 189.0
Dose inhomogeneity (PTV periphery dose/maximum dose) (%) 67 75 60 100.0
Fractionation
1×20–24 Gy 11 16.4
1×25–30 Gy 12 17.9
3–4×7–8 Gy 6 9.0
3×10–15 Gy 23 34.3
3×16–18 Gy 5 7.4
5×6–10 Gy 6 9.0
8×5–7.5 Gy 4 6.0
SBRT, stereotactic body radiotherapy; PTV, planning target volume; BED, biological effective dose.
Table 1 (continured)
Factors No. of patients/lesions % Median Minimum Maximum
Systemic therapy 4 weeks before SBRT 67
Yes 13 19.4
No 54 89.6
Systemic therapy after SBRT 67
Yes 27 40.3
No 40 59.7
SBRT, stereotactic body radiotherapy.
lesions (P=0.055). Patients receiving definitive treatment 
to all metastatic lesions had non-significantly improved 
survival compared to patients who were treated with systemic 
therapy and SBRT-debulking of disease with 3-year OS-rates 
of 50.5% and 14.6%, respectively (P=0.077). Multivariate 
analysis revealed higher Karnofsky performance score, lower 
maximum pulmonary metastasis diameter as well as no 
admission of systemic therapy after SBRT as independent 
prognostic factors for OS (P=0.014; P=0.049; P=0.006).
Toxicity
Acute toxicity was mild with only four patients developing 
radiation induced common terminology criteria for adverse 
events (CTCAE) grade II pneumonitis. Three of these four 
patients were treated with a second course of SBRT to another 
pulmonary metastasis within 14 days of initial SBRT. No 
grade III–V pneumonitis was reported. One patient died 0.9 
months following SBRT; consequently 30- and 60-day death 
rates were 1.5%. The death of this patient was not attributable 
to SBRT treatment, as it was secondary to perforated 
diverticulitis with peritonitis. Three patients developed further 
grade II+ toxicity: pulmonary fibrosis (1 patient), atelectasis 
(1 patient) and pleural effusion (1 patient). Higher toxicity rates 
were not observed in patients who received systemic therapy 
before SBRT.
4517Journal of Thoracic Disease, Vol 9, No 11 November 2017
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Figure 1 Outcome analysis. (A) Local control (LC) following SBRT for 67 lung metastases from RCC; (B) metastases treated with BEDISO 
≥130 Gy showed a tendency for superior LC (P=0.054). SBRT, stereotactic body radiotherapy; RCC, renal cell carcinoma.
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Table 3 Univariate analysis of prognostic factors influencing LC and OS
Factors
LC OS
HR 95% CI P HR 95% CI P
Sex (female vs. Male) 0.281 (0.025, 3.107) 0.130 0.622 (0.233, 1.659) 0.343
Age 1.094 (0.920, 1.303) 0.310 1.002 (0.953, 1.053) 0.946
Karnofsky performance scale 0.977 (0.879, 1.087) 0.673 0.962 (0.933, 0.991) 0.010
Histology (clear cell vs. other vs. unavailable) 0.523 (0.015, 18.071) 0.720 0.963 (0.837, 1.109) 0.603
Grade (1 vs. 2 vs. 3 vs. unknown) 0.564 (0.045, 7.124) 0.658 0.906 (0.787, 1.043) 0.169
Time to metastasis (synchronous vs. Metachronous) 0.542 (0.049, 5.998) 0.618 0.425 (0.177, 0.999) 0.055
Number of metastases (solitary vs. multiple) 3.343 (0.303, 36.876) 0.325 1.044 (0.431, 2.525) 0.924
Maximum pulmonary metastasis diameter 1.276 (0.588, 2.767) 0.537 1.339 (1.068, 1.677) 0.011
Tumor location (peripheral vs. central) 1.971 (0.178, 21.770) 0.580 0.433 (0.146, 1.287) 0.123
BEDPTV (PTV periphery) 0.997 (0.955, 1.041) 0.896 0.998 (0.986, 1.011) 0.795
BEDISO (PTV isocenter) 0.986 (0.962, 1.010) 0.250 1.000 (0.992, 1.007) 0.960
Total dose in BEDISO: <130 Gy; ≥130 Gy 0.012 (0.001, 37.987) 0.054 1.259 (0.583, 2.746) 0.553
Definitive treatment to all further metastases (yes vs. No) n n n 2.334 (0.911, 5.977) 0.077
Systemic therapy in general (no vs. yes) 0.666 (0.060, 7.352) 0.740 0.557 (0.252, 1.233) 0.149
Systemic therapy before SBRT (no vs. yes) 2.133 (0.193, 23.574) 0.537 0.673 (0.314, 1.444) 0.309
Systemic therapy 4 weeks before SBRT (no vs. yes) 3.641 (0.161, 36.767) 0.727 0.392 (0.139, 1.100) 0.075
Systemic therapy after SBRT (no vs. yes) 0.155 (0.013, 1.771) 0.133 0.190 (0.069, 0.527) 0.001
Systemic therapy 4 weeks after SBRT (no vs. yes) 0.721 (0.293, 1.322) 0.290 0.803 (0.622, 1.038) 0.094
The variables sex, histology, grade, time of metastasis, number of metastases; tumor location and total dose in BEDISO </≥ 130 Gy were 
analyzed as categorical variables, while the other variables were taken as continuous variables for analysis. n, calculation of confidence 
intervals was not possible due to too few cases and events in each single group. OS, overall survival; LC, local control; HR, hazard ratio; 
BED, biological effective dose; PTV, planning target volume; SBRT, stereotactic body radiotherapy. 
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Discussion
RCC is traditionally perceived to be a radioresistant 
malignancy with a limited role for radiotherapy in the 
management of localized disease (1). Although prospective 
trials investigating the role of radiotherapy in the neoadjuvant 
and adjuvant settings demonstrated improved LC, these 
findings have not translated into increased survival (40,41). 
Contrarily, smaller retrospective studies have suggested a 
potential advantage for adjuvant radiotherapy with larger 
tumors (pT3) or positive resection margins (40,42,43). 
Nevertheless, currently radiotherapy is primarily used for 
palliation of symptoms in metastatic RCC (3).
The efficacy of radiotherapy is highly dependent on 
applied doses and fractionation schemes. While RCC 
tumors appear to be radioresistant using conventionally 
fractionated radiotherapy, preclinical data suggest increased 
radiosensitivity of human RCC xenografts in nude mice 
when applying ablative, hypofractionated radiotherapy (44). 
In the clinical setting, dose escalation has also been shown 
to overcome radioresistance in RCC tumors: Zelefsky and 
colleagues reported 3-year LC of 88% following SBRT 
with high fractional doses for extracranial RCC metastases, 
while LC dropped to only about 20% when lower doses 
were used (30). A few other reports have also revealed 
LC rates of about 80–90% for extracranial SBRT in RCC 
patients (5,6,28,29,31,33). However, due to the limited 
number of RCC patients treated with SBRT, these reports 
combined data form different metastatic sites of including 
lung, bone, liver, lymph nodes or even primary RCC tumors 
(5,6,28,29,31,33). 
As LC and treatment-related toxicity following SBRT 
are known to be highly dependent on treatment location, it 
is essential to analyze different SBRT treatment locations 
separately. To our knowledge, this analysis is the first study 
focusing on SBRT for solely pulmonary metastases from 
RCC. We observed excellent 1- and 3-year LC rates of 
98.1% and 91.9% following SBRT of these metastases with 
low rates of treatment-associated toxicity. 
In general, the most important factor for achieving 
optimal LC following SBRT is a sufficiently high BED. For 
lung and liver SBRT, doses above 100 Gy BEDPTV (PTV 
minimum dose) are recommended, while lower doses seem 
sufficient for spinal metastases (35,36,45-47). A recently 
published report by Wang et al. investigated SBRT for a 
wide variety of extracranial RCC metastases, including bone 
(38.8%), abdominal (28.0%) and thoracic (20%) lesions, 
demonstrating significantly improved LC if a BEDPTV of 
98.7 Gy or higher was applied (28). Altoos et al. compared 
SBRT (n=36) and conventionally fractionated radiotherapy 
(n=17) for the treatment of thoracic, abdominal or soft 
tissue RCC metastases and also reported a BEDPTV 
≥100 Gy to be associated with significantly superior LC. In 
our study, excellent LC rates exceeding 90% after 3 years for 
RCC pulmonary metastases were detected, despite a median 
BEDPTV of 84.4 Gy. As in other studies, we also observed 
a dose-response relationship: if pulmonary metastases 
received a BEDISO ≥130 Gy at PTV isocenter, there was 
a strong trend for improved LC (P=0.054). Notably, only 
three local recurrences were identified in our cohort and 
hence this result has to be interpreted with caution. Due to 
the very low number of local relapses detected in this study, 
consequently analysis of further potential prognostic factors 
regarding LC was highly limited (Table 3) and results have 
to be regarded as preliminary. Clearly, larger, multi-center 
studies are needed to further clarify the impact of suspected 
prognostic factors. 
To date, only smaller and retrospective surgical series 
for pulmonary metastasectomy in RCC patients have 
reported good 3- and 5-year survival rates of 49–66% 
and 31–58%, respectively (Table 4) (17-27). In this study, 
estimated 3- and 5-year OS rates with 44% and 33% 
were slightly lower compared to these surgical series. 
However, comparison between these studies is limited, as 
nearly all patients in this study were classified as medically 
inoperable due to comorbidities or higher age. While 
median age was 68.5 years in this study, reported median 
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Figure 2 Overall survival (OS) after SBRT of 67 pulmonary 
metastases in 46 RCC patients. SBRT, stereotactic body 
radiotherapy; RCC, renal cell carcinoma.
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ages were 6–11 years lower in the surgical series, ranging 
from 57.7–62.0 years, potentially explaining the marginally 
lower OS rates observed in our study (17-19,21-23,25-27). 
Hence, SBRT for pulmonary metastases might be a valid 
alternative at least for patients in higher age and with 
comorbidities. 
A survival benefit for patients with oligo-metastatic 
RCC has been suggested when complete metastasectomy 
in parenchymal organs is performed compared to no 
surgical resection (10,13). However, patient selection for 
this treatment approach is critical. A recent review of 
local treatments for metastases of RCC recommended 
the following criteria for suitable patients for a curative 
approach: good performance status, solitary or oligo-
metastatic lesions, single organ sites, metachronous 
metastases, disease-free interval of over 2 years, absence 
of progression to treatment, and pulmonary metastasis 
size less than 4 cm in diameter in addition to several 
other, organ-specific factors (13). Corresponding to 
these recommendations, Karnofsky performance score 
and pulmonary metastasis diameter were identified as 
independent prognostic factors for superior OS in our 
study (P=0.010; P=0.009). Furthermore, a trend towards 
improved OS was detected for metachronous lesions when 
compared to synchronous metastases (P=0.055). Patients 
analyzed in the current study were mainly treated with 
pulmonary SBRT in a potentially curable oligo-metastatic 
tumor state. Thirty-six patients (83%) received definitive 
treatment including SBRT, surgery or radiotherapy with 
curative doses often in combination with systemic therapy 
to all detectable tumor lesions. However, 8 patients (17%) 
were treated with SBRT for debulking and palliation of 
disease in combination with systemic therapy. This group of 
patients experienced a worse median survival of 19.6 months 
following SBRT compared to those patients treated with 
curative intent with 29.8 months (P=0.077; Table 3). This 
finding may be explained by two mechanisms: (I) whether 
or not all lesions are radically treated maybe co-correlated 
with the overall metastatic tumor load, which is a known 
prognostic factor; (II) radical treatment of all imaging-
defined metastases does indeed improve OS compared to 
debulking SBRT only.
RCC is considered to be an immunogenic tumor. Until 
10 years ago, interferon alpha and high-dose interleukin-2 
were the mainstays of treatment for patients with metastatic 
RCC (3). Although these systemic agents have been replaced 
by molecular, targeted therapies during the last years, 
the immunogenic potential of RCC remains an exciting 
avenue for future study. Immunotherapy with antibodies 
against the programmed cell death protein 1 (PD-1) or its 
ligand 1 (PD-L1) have demonstrated excellent preliminary 
results (48-50). Interestingly, SBRT might also be applied 
to enhance immunogenic the anti-tumor response via the 
abscopal effect: clinical studies have described regression of 
non-irradiated distant lesions following SBRT to an RCC 
metastasis (51-53). This effect is hypothesized to be immune 
Table 4 Surgical series for pulmonary metastasectomy in RCC patients
Study Year Treatment years Number of patients (n) 3-year OS (%) 5-year OS (%)
Piltz et al. (20) 2002 1980–2000 105 54 40
Pfannschmidt et al. (19) 2002 1985–1999 191 – 37
Murthy et al. (18) 2005 1986–2001 92 49 31
Hofmann et al. (17) 2005 1975–2003 64 – 33
Assouad et al. (21) 2007 1984–2005 65 – 34
Kanzaki et al. (22) 2010 1973–2008 48 60 47
Meimarakis et al. (23) 2011 1986–2006 202 – 39
Kawashima et al. (25) 2011 1998–2008 25 53 36
Bölükbas et al. (24) 2012 1999–2008 107 – 47
Kudelin et al. (26) 2013 1999–2009 116 – 49
Renaud et al. (27) 2014 1993–2011 122 66 58
Own data 2017 2001–2016 46 44 33
RCC, renal cell carcinoma; OS, overall survival.
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mediated (40,53). However, the abscopal effect occurs rarely 
after SBRT alone and might be fostered by simultaneous 
treatment with synergistic immunomodulatory agents 
(40,53). Hence, a potential future application of SBRT in 
patients with metastatic RCC might include the addition of 
systemic immunomodulatory therapy by inducing persistent 
anti-tumor immunity and potentially improving long-term 
survival (40,53).
Limitations of this study were mainly caused by the 
retrospective nature of this analysis. Despite the extensive 
study timespan and multi-institutional approach, patient 
numbers were quite low as only few RCC patients are 
treated with SBRT to pulmonary metastases. The median 
follow-up time of 28.3 months for all patients was too short 
to assess long-term LC, survival and potentially late toxicity. 
Furthermore, systemic treatments have drastically changed 
over the course of this study, and their improved efficacy 
may have influenced LC and survival following SBRT. 
Conclusions
SBRT especially with BEDiso ≥130 Gy for pulmonary RCC 
metastases resulted in excellent LC with only minimal acute and 
late toxicity. Survival was favorable for metastatic RCC patients. 
Future studies are needed to evaluate the potential of SBRT in 
combination with target molecular agents and/or immunotherapy 
in the treatment of oligo-metastatic RCC patients.
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